Received: 30 November 2021
Accepted: 19 February 2022
First Online: 28 February 2022
: As this was a retrospective review of cases, ethics approval and consent was not required. The patients in the case series did sign informed consent prior to receipt of CAR T-cell therapy.
: The authors obtained verbal consent from the patients to publish their experience as a case series.
: BH reports honoraria from Kite Pharma, BMS, ADC Therapeutics, Janssen, and Novartis. The other authors declare that they have no competing interests relevant to this case series.